Armata Pharmaceuticals

The 'Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024' report by ResearchAndMarkets.com covers 10+ companies and 12+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key drugs include Armata Pharmaceuticals' AP-PA02 in Phase II and BiomX's BX004 in Phase I/II.

The 'Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024' report highlights emerging therapies like Brensocatib and HSK31858, which aim to address the underlying mechanisms of NCFB, potentially improving patient quality of life. Key industry players are actively developing these therapies, with significant implications for managing NCFB.

Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.

Armata Pharmaceuticals, Inc. announced that CEO Deborah Birx will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 11, 8:00-8:30 AM ET. The company focuses on bacteriophage therapeutics for antibiotic-resistant infections.

Iovance Biotherapeutics' MDA-TIL trial terminated due to lack of efficacy, leading to drops in Phase Transition Success Rates (PTSR) in various cancers. Sention Therapeutics' ST-1891 and Armata Pharmaceuticals' APPA-02 trials completed successfully in hypothyroidism and bronchiectasis, respectively, boosting their PTSRs. Karyopharm Therapeutics' Xpovio trial in metastatic melanoma and Worg Pharmaceuticals Hangzhou's WP-1302 trial in Graves' disease were terminated, affecting their PTSRs negatively.